

**Filed On Behalf Of:**

Novartis AG

**By:**

Nicholas N. Kallas  
NKallas@fchs.com  
ZortressAfinitorIPR@fchs.com  
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

**ROXANE LABORATORIES, INC.,**  
Petitioner,

v.

**NOVARTIS AG,**  
Patent Owner.

---

Case IPR2016-01461  
Patent 9,006,224

**PATENT OWNER'S MANDATORY NOTICES  
UNDER 37 C.F.R. § 42.8(a)(2)**

**REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)**

Pursuant to the requirements of 37 C.F.R. § 42.8(a)(2), the undersigned states that Novartis AG (“Novartis” or “Patent Owner”) owns U.S. Patent No. 9,006,224 (“the ’224 Patent”). Novartis is the real party-in-interest in IPR2016-01461.

**RELATED MATTERS PURSUANT TO 37 C.F.R. § 42.8(b)(2)**

The ’224 Patent has been asserted in the following patent infringement lawsuits: (1) Novartis Pharm. Corp. et al. v. Roxane Labs., Inc., No. 15-474-RGA (D. Del.); and (2) Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 15-475-RGA (D. Del.) (order dismissing proceeding filed October 15, 2015).

The ’224 Patent is also the subject of the following Petition for *Inter Partes* Review: Novartis AG v. Par Pharm., Inc., *Inter Partes* Review No. 2016-01479 (P.T.A.B.).

Other patent infringement lawsuits involving different patents that cover the same product as the proceedings above include:

(1) Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 14-1494-RGA (D. Del.); (2) Novartis Pharm. Corp. et al. v. Roxane Labs., Inc., No. 14-1508-RGA (D. Del.); (3) Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 15-78-RGA (D. Del.); (4) Novartis Pharm. Corp. et al. v. Roxane Labs., Inc., No. 15-128-RGA (D. Del.); (5) Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 15-1050-RGA (D.

Del.); and (6) Novartis Pharm. Corp. et al. v. Breckenridge Pharm., Inc., No. 16-431-RGA (D. Del.).

Other *Inter Partes* Review proceedings involving different patents that cover the same product as the proceedings above include:

- **U.S. Patent No. 5,665,772:** (1) Novartis AG v. Par Pharm., Inc., *Inter Partes* Review No. 2016-00084 (P.T.A.B.); (2) Novartis AG v. Breckenridge Pharm., Inc., *Inter Partes* Review No. 2016-01023 (P.T.A.B.); (3) Novartis AG v. Par Pharm., Inc., *Inter Partes* Review No. 2016-01059 (P.T.A.B.); (4) Novartis AG v. Roxane Laboratories, Inc., *Inter Partes* Review No. 2016-01102; and (5) Novartis AG v. Breckenridge Pharm., Inc., *Inter Partes* Review No. 2016-01103 (P.T.A.B.).
- **U.S. Patent No. 7,741,338:** Novartis AG v. Par Pharm., Inc., *Inter Partes* Review No. 2016-00074 (P.T.A.B.) (Order Terminating Proceeding filed April 1, 2016).
- **U.S. Patent No. 7,297,703:** Novartis AG v. Par Pharm., Inc., *Inter Partes* Review No. 2016-00075 (P.T.A.B.) (Order Terminating Proceeding filed April 1, 2016).

**IDENTIFICATION OF LEAD AND BACK-UP COUNSEL  
PURSUANT TO 37 C.F.R. §§ 42.8(b)(3) and 42.10**

Pursuant to 37 C.F.R. §§ 42.8(b)(3) and 42.10, Novartis designates Nicholas N. Kallas (Reg. No. 31,530) as lead counsel and Raymond R. Mandra (Reg. No. 34,382) as back-up counsel.

A power of attorney from Novartis is being submitted with this Notice.

**SERVICE INFORMATION PURSUANT TO 37 C.F.R. § 42.8(b)(4)**

Novartis may be served electronically using the following e-mail address:

ZortressAfinitorIPR@fchs.com

Novartis may be served by postal mailing, hand-delivery, telephone or facsimile as follows:

Nicholas N. Kallas  
Fitzpatrick, Cella, Harper & Scinto  
1290 Avenue of the Americas  
New York, NY 10104  
Telephone: (212) 218-2100  
Facsimile: (212) 218-2200

Respectfully submitted,

Dated: August 9, 2016

/ Nicholas N. Kallas /  
Nicholas N. Kallas  
Registration No. 31,530  
Lead Counsel for Patent Owner  
FITZPATRICK, CELLA, HARPER  
& SCINTO  
1290 Avenue of the Americas

New York, NY 10104-3800  
Tel. 212-218-2100

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.